<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001023</url>
  </required_header>
  <id_info>
    <org_study_id>DATRI 001</org_study_id>
    <secondary_id>11732</secondary_id>
    <nct_id>NCT00001023</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients</brief_title>
  <official_title>Evaluation of the Safety, Tolerance and Pharmacokinetics of Rifabutin/Clarithromycin Combination and Rifabutin/Azithromycin Combination in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      PER 03/10/94 AMENDMENT: PART B. To determine whether there is an effect on plasma drug levels&#xD;
      of azithromycin and rifabutin as measured by changes in the plasma concentration-time curve&#xD;
      (AUC) when these drugs are taken concomitantly.&#xD;
&#xD;
      ORIGINAL PRIMARY: To gain preliminary information about the safety and tolerance of&#xD;
      clarithromycin and azithromycin in combination with rifabutin (three potential agents against&#xD;
      Mycobacterium avium-intracellulare) in HIV-infected patients with CD4 counts &lt; 200 cells/mm3.&#xD;
&#xD;
      ORIGINAL SECONDARY: To determine whether there is an effect on the pharmacokinetics of the&#xD;
      macrolide antibiotics or rifabutin when these drugs are taken concomitantly. To monitor the&#xD;
      effect of rifabutin therapy on dapsone serum levels in patients taking dapsone for PCP&#xD;
      prophylaxis. To monitor the effect of macrolide/rifabutin combination therapies on AZT or ddI&#xD;
      serum levels.&#xD;
&#xD;
      Two new macrolide antibiotics, clarithromycin and azithromycin, and rifabutin (a rifamycin&#xD;
      derivative) have all demonstrated in vitro and in vivo activity against Mycobacterium&#xD;
      avium-intracellulare, a common systemic bacterial infection complicating AIDS. Further&#xD;
      information is needed, however, regarding the clinical and pharmacokinetic interaction of&#xD;
      these drugs used in combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two new macrolide antibiotics, clarithromycin and azithromycin, and rifabutin (a rifamycin&#xD;
      derivative) have all demonstrated in vitro and in vivo activity against Mycobacterium&#xD;
      avium-intracellulare, a common systemic bacterial infection complicating AIDS. Further&#xD;
      information is needed, however, regarding the clinical and pharmacokinetic interaction of&#xD;
      these drugs used in combination.&#xD;
&#xD;
      AMENDED 03/10/94 (Part B): Approximately 38 HIV-infected or uninfected subjects are&#xD;
      randomized to receive azithromycin or rifabutin (Groups 3 and 4) daily for 14 days, followed&#xD;
      by a combination regimen of both drugs for 4 additional weeks. Patients are followed weekly.&#xD;
      Pharmacokinetic sampling will be performed on days 14, 15, and 42-45.&#xD;
&#xD;
      ORIGINAL: Sixty-eight patients are randomly assigned to one of four groups (17 patients per&#xD;
      group). They receive either clarithromycin or azithromycin in combination with rifabutin on&#xD;
      one of two different dosing schedules. Patients receive medication for 6 weeks and undergo&#xD;
      follow-up weekly during drug administration and at week 8.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 1998</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>91</enrollment>
  <condition>Mycobacterium Avium-intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Primary or secondary PCP prophylaxis with TMP/SMX, dapsone, or aerosolized&#xD;
             pentamidine.&#xD;
&#xD;
          -  Any approved therapy for antiretroviral treatment, or antiretroviral therapy available&#xD;
             through FDA-sanctioned treatment IND or treatment protocol.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
        AMENDED (PART B):&#xD;
&#xD;
          -  Either HIV infection OR no HIV infection.&#xD;
&#xD;
          -  CD4 count unspecified.&#xD;
&#xD;
        ORIGINAL:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 count &lt; 200 cells/mm3 within 90 days prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Known Mycobacterium avium-intracellulare (MAI) bacteremia or presence of a clinical&#xD;
             syndrome compatible with MAI (i.e., fevers, weight loss, elevated LDH and alkaline&#xD;
             phosphatase).&#xD;
&#xD;
          -  Fever = or &gt; 38.5 deg C (100.4 deg F) within 7 days prior to study entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acute or chronic use of phenobarbital, carbamazepine, rifampin, dilantin, fluconazole,&#xD;
             itraconazole, ketoconazole, ciprofloxacin, beta-blockers, or clarithromycin.&#xD;
&#xD;
          -  Oral contraceptives.&#xD;
&#xD;
          -  Acute therapy for an AIDS-related opportunistic infection or malignancy, or other&#xD;
             acute medical illness, or infection.&#xD;
&#xD;
          -  Maintenance therapy for CMV, cryptococcal meningitis, or toxoplasmosis.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of intolerance or hypersensitivity to study drugs, other macrolide&#xD;
             antibiotics, or rifampin.&#xD;
&#xD;
          -  Three or more loose bowel movements per day within 3 months prior to study entry.&#xD;
&#xD;
          -  Unintentional weight loss &gt;= 5 percent of body weight within 3 months prior to study&#xD;
             entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Rifabutin within 30 days prior to study entry.&#xD;
&#xD;
          -  Clarithromycin or azithromycin within 14 days prior to study entry.&#xD;
&#xD;
          -  Acute therapy for an AIDS-related opportunistic infection or malignancy, or other&#xD;
             acute medical illness, or infection within 28 days prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Blood transfusions within 1 month prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Hafner</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>H Standiford</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Arizona / Health Science Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Veterans Affairs Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health Dept</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>802044507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Maryland at Baltimore / Veterans Adm</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rhode Island / Roger Williams Med Ctr</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Virginia / School of Pharmacy</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>232980533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hafner R, Bethel J, Standiford HC, Follansbee S, Cohn DL, Polk RE, Mole L, Raasch R, Kumar P, Mushatt D, Drusano G; DATRI 001B Study Group. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother. 2001 May;45(5):1572-7. doi: 10.1128/AAC.45.5.1572-1577.2001.</citation>
    <PMID>11302832</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifabutin</keyword>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Clarithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

